Gyroscope Therapeutics ^Companies

Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye. The company's main goal is to explore the convergence of advancements made in the understanding of the complement system's impact on eye disease, the genetic basis of Age-related Macular Degeneration (AMD), and gene therapy as a mode of treatment delivery. Their lead investigational gene therapy, GT005, is designed to restore balance to an overactive complement system by increasing the production of the Complement Factor I protein. Gyroscope Therapeutics was founded in 2016 and is currently conducting Phase I/II and Phase II clinical trials for GT005.